Pablo Cagnoni, Rubius CEO
Rubius chief lays out the first human data on their lead red cell drug in a comeback play. And the stock skyrockets
Rubius $RUBY CEO Pablo Cagnoni is facing a critical and closely-watched test today.
Almost exactly a year after watching the biotech’s shares routed after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
